Syndax Pharmaceuticals Inc. trading above issue price in Nasdaq debut
Shares of Syndax Pharmaceuticals , a cancer-focused biotechnology company, were trading at $12.44 Thursday morning, above the company's initial public offering issue price of $12 in its debut on the Nasdaq. With the offering, Syndax sold 4.4 million shares to raise $52.8 million. The company had previously set a price range of $14 to $16. Morgan Stanley, Citigroup, JMP Securities and Oppenheimer were the underwriters for the offering.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.